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Tuberculosis Elimination Revisited: Obstacles,
Opportunities, and a Renewed Commitment
Advisory Council for the Elimination of Tuberculosis (ACET)
Summary
In 1989, CDC and the Advisory Council for the Elimination of Tuberculosis
(ACET) issued  A Strategic Plan for the Elimination of Tuberculosis in the United
States. Since then, the United States has experienced a resurgence of tuberculo-
sis (TB) followed by a successful mobilization against the epidemic. Because the
nature of this disease has changed during the past decade, ACET has reassessed
its 1989 plan. Recent progress against TB should reinforce the nation’s confi-
dence that the disease can be controlled and ultimately eliminated. However,
existing TB-control efforts must be sustained and enhanced, and new and im-
proved diagnostic, treatment, and prevention methods, including a new vaccine,
must be developed and applied. Support for these efforts should be broad-
based and include the establishment of new partnerships. Because eliminating
TB in the United States will have widespread economic, public health, and social
benefits, committing to this action will also fulfill an obligation to persons
throughout the world who have this preventable and curable disease. With this
reassessment, ACET reaffirms its call for the elimination of TB in the United
States.
INTRODUCTION
In 1989, CDC and the Advisory Council for the Elimination of Tuberculosis (ACET)
issued A Strategic Plan for the Elimination of Tuberculosis in the United States (1 ).
This plan established a national goal of tuberculosis (TB) elimination, defined as a
case rate of less than 1/1,000,000 population by 2010, with an interim target of
3.5/100,000 population by the year 2000. The plan also described the following actions
needed to achieve TB elimination: a) more effective use of existing prevention and
control methods, especially among high-risk populations; b) development and evalu-
ation of new technologies for TB diagnosis, treatment, and prevention; and c) rapid
transfer of newly developed technologies into clinical and public health practice. For
the past 10 years, this plan has provided the framework for the nation’s TB-control
efforts, including a successful mobilization against the resurgence of TB associated
with a) deterioration of the public health infrastructure, b) increasing cases among
foreign-born persons, c) human immunodeficiency virus (HIV) infection, and d) trans-
mission of multidrug-resistant TB (MDR TB) in institutional settings (2 ).
However, TB in the United States has changed during the past decade. Since 1993,
TB morbidity has steadily declined, and the disease is more likely to occur in well-
defined risk groups and geographic areas that can be targeted for control efforts. But
new diagnostic and therapeutic tools are needed to continue the recent progress
toward TB elimination (3 ). In addition, a growing awareness that the worldwide TB
epidemic has implications for the United States has led to increased U.S. involvement
in the global battle against TB and an initiative to develop an effective vaccine (4,5 ).
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Finally, changes in the organization, delivery, and financing of health care have cre-
ated new challenges for TB elimination (6 ). 
Thus, ACET, which provides advice and recommendations regarding the elimina-
tion of TB to the U.S. Department of Health and Human Services and CDC, reassessed
its 1989 plan and made updated recommendations for TB elimination. In its reassess-
ment, ACET concluded that the past decade of progress against TB should reinforce
the nation’s confidence in the following concepts:
• TB can be controlled and ultimately eliminated with the development of new
tools and expanded partnerships.
• TB elimination will have widespread economic, public health, and social benefits.
• Committing to decisive action against TB in the United States will fulfill an obli-
gation to persons throughout the world who have this preventable and curable
disease.
BACKGROUND
The Changing Epidemiology of TB
During 1953–1985, the number of TB cases reported annually in the United States
dropped 74%, from 84,304 to 22,201. Subsequently, this trend stopped. In 1989, when
CDC issued its TB elimination plan, reported TB cases had increased approximately
5% over the previous year; cases continued to rise, reaching a peak of 26,673 in 1992
(7 ). This resurgence was associated with a) the HIV epidemic, which substantially in-
creased the risk for active TB among persons with latent TB infection; b) immigration
from TB-endemic countries; c) TB transmission in congregate settings (e.g., hospitals
and prisons); d) deterioration of the infrastructure for TB services; and e) development
of difficult-to-treat cases of MDR TB (8 ).
Studies conducted during this period of TB resurgence indicated substantial, on-
going transmission of TB and development of active TB in many recently infected
persons (9,10 ). This phenomenon appeared to primarily affect certain high-risk popu-
lations (e.g., persons who were HIV-infected, homeless, or incarcerated), suggesting
the existence of several concurrent TB epidemics in the United States. The resurgence
of TB during 1985–1992 was accompanied by an increase in the number of persons
with MDR TB, largely because of MDR TB outbreaks among HIV-infected persons in
institutional settings (11 ). The rise in total TB cases, coupled with increased drug
resistance, has challenged state and local control efforts (2 ).
Since 1992, the number of reported TB cases in the United States has decreased
each year, reaching a record low of 18,361 in 1998, with a case rate of 6.8/100,000 and
an overall decline of 31% (CDC, unpublished data, 1998). This reduction is attributed
to more effective TB-control programs that emphasize prompt identification of per-
sons with TB, prompt initiation of appropriate therapy, and efforts to assure that
therapy will be completed (12 ).
The recent success in TB control in the United States is tempered by the burden of
TB among foreign-born persons residing in this country. An increasing percentage of
U.S. cases are occurring among persons who were born in Asian, African, or Latin
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American countries, where TB rates are 5–30 times higher than U.S. rates (13 ). During
1992–1997, the number of TB cases among U.S.-born persons declined 38%, whereas
the number of TB cases among foreign-born persons in the United States increased
6%. The TB case rate for foreign-born persons has remained at least 4–5 times higher
than that for U.S.-born persons, and the proportion of U.S. cases occurring in foreign-
born persons has increased steadily since the mid-1980s, reaching 42% in 1998 (CDC,
unpublished data, 1998).
Rebuilding the Public Health Infrastructure
Following the resurgence of TB and the emergence of MDR TB as a public health
threat, federal resources were increased to a) strengthen TB surveillance, b) improve
laboratory capacity for identifying mycobacterial species and conducting real-time
drug susceptibility testing, c) expand the use of directly observed therapy (DOT), and
d) expedite investigation of the close contacts of TB patients. The subsequent 31%
decrease in annual TB cases during 1992–1998 is a notable public health achievement
and a measurable return on the resources invested to strengthen TB-control programs
nationwide. Increasing the number of patients who complete TB therapy, including
those in hard-to-reach populations, has contributed to these reductions. In many
areas, TB screening and preventive therapy services directed toward high-risk groups,
especially persons at risk for HIV infection and persons in correctional facilities,
have expanded substantially. Surveillance data and research on adherence to treat-
ment have better characterized risk groups, leading to more effective, targeted
interventions.
Additionally, training and educational activities and products are increasingly avail-
able nationwide for health-care providers. New materials are developed as needed to
address the changing TB epidemiology and scientific advances in diagnosis and treat-
ment. ACET has issued several statements on TB-control practices, which are
available on the Internet (14 ). Three model TB centers were established in 1994 as
national educational resources to provide TB services, expert consultation, and train-
ing for health-care providers. In 1999, these centers worked with CDC to develop the
Strategic Plan for Tuberculosis Education and Training to guide efforts in this area
during the next 5 years (15 ).
Despite these efforts, DOT and other measures to improve timely completion of
treatment are underused in many areas of the country (16 ). The investigation of con-
tacts of infectious patients and the treatment of persons with latent TB infection are
often inadequate. Although the numbers of cases have again started to decline in
some areas, TB continues to be a serious public health threat requiring resources to
maintain and enhance recent gains in prevention and control (17 ).
Changes in Health Care Organization and Delivery
The marked changes in providing and financing health care in the United States
during the past decade present both challenges and opportunities for TB control.
Approximately 80 million persons in the United States are enrolled in health mainte-
nance organizations (6 ). Managed care programs serve one third of Medicaid
beneficiaries, with enrollment in such programs growing 30%–40% annually (18 ).
Opportunities exist for TB-control programs to work with health-care providers in
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managed care programs to provide high-quality, preventive TB services to persons at
high risk (19 ). Providing such services could be cost-saving (20 ). However, the extent
to which managed care programs can provide optimal TB surveillance and reporting,
as well as treatment and prevention services, is uncertain, especially in regard to the
many previously uninsured persons now covered by managed care plans.
Recognition of the Interdependence of Global TB and TB in the
United States
Worldwide, approximately 8 million cases and 2 million deaths were attributed to
TB in 1998 (21 ). A close relationship exists between the global TB problem and the
impact of the disease in the United States. TB cases among foreign-born persons
residing in the United States could soon outnumber cases among U.S.-born persons.
Thus, TB elimination in the United States will not be possible without a substantial
reduction in the global TB burden. However, global TB-control efforts are hampered
by several barriers, including the failure of some developing countries and donor
countries to fund effective TB-control programs. The World Health Organization
(WHO) estimates that, in 1997, only 32% of the world’s population was living in areas
where effective TB-control programs were fully implemented and operational (22 ). In
many countries in sub-Saharan Africa, HIV infection has led to the doubling and
tripling of TB cases, threatening to overwhelm TB-control programs in these countries
(23 ). None of the strategies for TB control recommended for low-income countries
appears to have decreased the number of HIV-associated TB cases. Moreover, MDR TB
has emerged as a serious problem in many countries (24 ). Treatment of MDR TB is
expensive and beyond the resources of most developing nations, and increases in
MDR TB threaten global TB-control efforts and add urgency to the push for effective
interventions worldwide.
WHO has developed a control strategy known as directly observed therapy, short-
course (DOTS), which requires microscopy-based diagnosis, standardized treatment
under direct supervision, a secure supply of quality drugs and equipment, careful
monitoring and supervision, and political commitment to support these activities
(25 ). WHO has advocated for increased assistance from wealthier countries to
support DOTS programs that require outside assistance. Other international organiza-
tions have joined the call for increased U.S. support for global TB control; as a result,
U.S. participation has increased, particularly through the U.S. Agency for International
Development (USAID).
Scientific Advances
An important component of the 1989 TB elimination plan was the call for develop-
ment of new tools for TB diagnosis, treatment, and prevention. In 1989, Public Health
Service support for TB research totaled less than $5 million. With a renewed interest
in TB, funding for research has increased. The National Institutes of Health
(NIH) spends approximately $60 million/year, and CDC provides approximately
$15 million/year. Although this expanded research has not had time to produce break-
throughs, progress has been made.
Since 1989, advances have been made in applied TB diagnostics, including new
methods that reduce the time needed to detect growth of Mycobacterium tuberculosis
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in diagnostic specimens (26 ). New rapid-detection methods using nucleic acid ampli-
fication techniques that provide results within hours have been licensed for use in the
United States (27 ). Rapid methods to identify drug-resistant TB (28 ), a new blood test
for latent TB infection based on the detection of gamma-interferon (29 ), and serodiag-
nosis based on a combination of purified mycobacterial antigens (30,31 ) are under
investigation. DNA fingerprinting methods (e.g., restriction fragment length polymor-
phism [RFLP] analysis) have been used to identify M. tuberculosis strains implicated
in outbreaks and laboratory contamination events, and the role of these methods in
detecting ongoing community TB transmission is being assessed (32 ).
Slower progress is being made in TB drug development, although recent advances
have been made in understanding the mechanisms of drug action and antibiotic resis-
tance. These advances are contributing to the identification of novel drug targets and
the development of new classes of therapeutic agents. NIH has increased support for
TB drug discovery, providing for in vitro screening and animal testing of new com-
pounds and evaluating promising therapeutic interventions in Phase I/II studies
through the Tuberculosis Research Unit. In 1997, CDC established the TB Trials Con-
sortium (TBTC) to undertake clinical trials of new drugs for treatment and prevention
in the United States. TBTC provided data that helped the U.S. Food and Drug Admini-
stration (FDA) approve rifapentine in 1998, the first new TB drug approved in more
than 25 years (33 ). Clinical trials of short-course treatment of latent TB infection sup-
ported by NIH and CDC led to CDC recommendations for the use of a 2-month
regimen of rifampin and pyrazinamide as an alternative to longer courses of isoniazid
(34,35 ). Despite the need for new drugs, few pharmaceutical companies are involved
in TB drug development (36 ).
A major research effort is also directed toward developing new TB vaccines. In its
recent statement calling for the development of a new TB vaccine, ACET reviewed
research progress in this area (4 ). The successful cloning of the complete genome of
M. tuberculosis should accelerate vaccine development (37 ), and several candidate
vaccines should be available for human testing within the next few years. In 1998,
NIH’s National Institute for Allergy and Infectious Diseases (NIAID), CDC’s National
Vaccine Program Office (NVPO), and ACET issued the Blueprint for Tuberculosis Vac-
cine Development (5 ), which concluded that a safe and protective TB vaccine could be
developed, but that the effort required a sustained commitment (i.e., 20 years and
approximately $800 million) and international, as well as public- and private-sector
collaboration.
TB ELIMINATION REVISITED AND REAFFIRMED
Since ACET’s TB elimination plan was published in 1989, other groups of experts
have analyzed the prospects for TB elimination and eventual eradication. The Office of
Technology Assessment of the U.S. Congress studied TB in the United States in the
early 1990s and concluded that “with an estimated one third of the world’s population
infected with TB and the relative mobility of people in and out of the United States
through immigration and tourism, the complete eradication of tuberculosis from this
country is unlikely in the foreseeable future” (38 ). The International Task Force for
Disease Eradication conducted an evaluation of eradicable diseases and listed TB
among those diseases that are not now eradicable, citing a need “for more accurate,
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rapid diagnostic tests, shorter and less expensive therapies, better case findings in
persons at risk, and a safer, more effective vaccine” (39 ).
Based on these observations, ACET reevaluated the feasibility of TB elimination in
the United States and acknowledged that limitations in available tools for diagnosis,
surveillance, and intervention are major barriers to disease elimination. In 1998, ACET
called for a concerted and sustained national effort to develop an effective new TB
vaccine, stating that “without a breakthrough in intervention strategy (i.e., a new TB
vaccine), the global toll of TB will not be reduced substantially nor will the disease be
eliminated in the United States” (4 ).
Approximately 18,000 new TB cases occur annually in the United States, and
approximately 15 million persons have latent TB infection with the attendant risk for
future disease. Costly TB outbreaks continue to occur, and MDR TB continues to
spread. Despite recent progress, 43 states and the District of Columbia reported at
least one MDR TB case during 1993–1997 (40 ). As a result, the annual cost of TB in the
United States approaches $1 billion (41 ).
TB is a serious health problem that disproportionately affects disenfranchised per-
sons. The existence of widespread racial and ethnic disparities in the incidence of TB
in the United States demonstrates the need for more effective control, as well as for
public policies that address the underlying causes of health disparities (42 ). An initia-
tive to eliminate TB in the United States could help reduce the disease worldwide and
serve as an example to other nations that recognize both the social and economic
benefits of reducing the TB burden.
Despite obstacles, ACET reaffirms its commitment to eliminating TB in the United
States. ACET encourages CDC to continue work initiated with the National Academy
of Sciences’ Institute of Medicine to review additional science and policy strategies
that could aid this goal. Sustained commitment from the nation’s scientific estab-
lishments is also required, and effective partnerships that extend beyond traditional
TB-control alliances will be indispensable. ACET urges further strengthening of the
TB-control infrastructure in the United States to apply the aggressive measures that
proved effective in reducing TB cases in the 1990s. ACET also recommends the devel-
opment of new diagnostic, therapeutic, and preventive tools, the most important of
which is a new, effective vaccine.
RECOMMENDATIONS
To move from TB control to TB elimination in the United States, existing efforts
must be sustained and enhanced, and new and improved diagnostic, treatment, and
prevention methods, including a new vaccine, must be developed and applied. Sup-
port for these activities should be broad-based and include the establishment of new
partnerships. TB elimination in the United States also will require recommitting to the
global battle against the disease.
Tailor Prevention, Control, and Elimination Strategies Based
on Local Epidemiology
The prevention, control, and elimination strategies of TB programs in the United
States must be tailored to the local or regional epidemiology of TB. Several concurrent
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epidemics are occurring across the United States and within individual states.
Incidence rates vary, as does the quality of control programs. Some low- and medium-
incidence states have high-incidence rates in certain local communities, and
high-incidence states are likely to have some areas of low incidence. Identifying the
spectrum of TB morbidity and the status of TB control within communities, as well as
the changes in these over time, allows for variations in interventions (i.e., TB-control
efforts in some areas and TB-elimination strategies in others), with resources reallo-
cated as needed. ACET recommends the following steps to enhance local TB control:
• All TB programs should develop or update a strategic plan for elimination within
their jurisdictions that is based on local surveillance and program evaluation data
and targeted to local needs. Programs should include approaches for maintain-
ing control efforts as prevention interventions are expanded.
• Programs should ensure the effective implementation of the highest priority
activities. These are a) diagnosing all TB cases and ensuring that patients com-
plete appropriate therapy, b) enhancing the effectiveness of contact investigation
activities and ensuring the prompt identification and completion of treatment of
contacts with latent TB infection, and c) expanding the testing and treatment of
latent TB infection to persons in other high-risk populations (43 ).
• TB programs that successfully perform the highest-priority activities and have
declining morbidity should begin developing and implementing plans for the
next level of priority activities, based on local epidemiologic findings.
• TB programs in low-incidence areas that are successfully performing control and
prevention activities and experiencing continued declines in morbidity should set
goals for achieving TB elimination (e.g., no transmission of M. tuberculosis or no
cases among the U.S.-born population in certain counties or regions of a state).
• State health departments should ensure timely responses to outbreaks or case
clusters and make available adequate laboratory services and medical consult-
ation for local areas with low or declining TB rates but inadequate expertise or
infrastructure. Depending on local circumstances, these resources might be
available only at the state, regional, or federal level.
Establish New Strategic Partnerships and Reach New
Stakeholders
Enhancing prevention and control efforts and eliminating TB will require new stra-
tegic partnerships to more effectively reach persons at risk for infection and to
broaden the base of support for elimination. ACET recommends the following steps to
achieve this goal:
• TB programs should broaden collaborations with other public health programs,
community-based organizations, and other groups that serve populations at risk
for TB infection to more effectively reach these populations and expand services
for targeted testing and treatment of latent TB infection.
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• TB-control programs should work through state and local health departments to
ensure participation in the development of contracts and agreements between
managed care programs and large health-care purchasers (e.g., state health
departments) to ensure provision of TB services to populations covered by these
programs.
• TB education that targets private providers, managed care plans, and new part-
ners must be intensified, as outlined in the Strategic Plan for Tuberculosis
Training and Education (15 ).
Enhance the Use of Current Tools for TB Prevention and
Control
Existing TB prevention and control tools have helped reduce morbidity in many
parts of the United States. But closer examination of surveillance and program evalu-
ation data reveals missed opportunities and areas for improvement. Although
completion of therapy rates have improved, therapy is often prolonged, which is an
inefficient use of staff time and resources. Substantial proportions of infected contacts
do not start treatment or do not complete treatment, hindering efforts to prevent
future TB cases. The large number of persons in the United States with latent TB infec-
tion and the high prevalence of TB infection among immigrants will continue to
produce new cases of active TB unless effective strategies are better applied. Strate-
gies that target groups at high risk for TB infection and treat those infected have often
been poorly applied. Deficiencies in the quality and completeness of surveillance data
also will hinder the ability of TB programs to develop effective elimination plans.
Sharpening the effectiveness of existing tools can accelerate the recent progress in TB
prevention and control. ACET recommends the following steps to achieve this goal:
• TB programs should develop plans to ensure the timely and complete reporting
of TB cases and to improve the quality of surveillance data.
• TB programs should develop and implement systems to conduct active case
finding among high-risk populations, when appropriate.
• DOT and other adherence-promoting measures should be expanded to improve
and reduce delays in completion of therapy.
• Fixed-dose combinations of anti-TB medications should be used for all patients
with active disease who are receiving self-administered, rifampin-containing
therapy. Combination drugs are likely to facilitate adherence to treatment and
reduce the risk for acquired drug resistance associated with erratic treatment.
• Operational research should be undertaken to develop strategies to ensure
that contacts are identified for all TB patients and to increase a) the number of
appropriate contacts identified for each patient, b) the proportion of infected
contacts starting therapy, and c) the proportion of infected contacts completing
therapy.
• TB-control staff members should be trained to use local epidemiologic data to
identify high-risk groups appropriate for targeted testing and to ensure that a
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greater proportion of infected persons begin and complete therapy (including
short-course regimens for treatment of latent TB infection, when appropriate).
• TB programs should work closely with community organizations (e.g., managed
care programs, community health clinics, immigrant groups) to expand testing
and treatment of latent TB infection among targeted populations and to ensure
that these activities are monitored and evaluated appropriately.
• National resources for TB education and training should be maintained as the
Strategic Plan for Tuberculosis Education and Training is fully implemented (15 ).
CDC should work with state and local programs to address training and educa-
tion needs and gaps. Improved collaboration between agencies and training
organizations is needed.
• TB programs should develop and implement systems for ongoing evaluation of
TB prevention and control activities to maximize effectiveness.
Develop New Tools for Elimination
Although improving the application of current tools can enhance TB prevention
and control efforts, new technologies must be developed, then quickly and appropri-
ately implemented to accelerate the decline and elimination of TB. An effective
vaccine would have the greatest impact on controlling and ultimately eliminating TB.
Better diagnostic and treatment methods are needed to improve the accuracy, speed,
and effectiveness of existing diagnostic and treatment measures. This country’s
research program must be expanded to capitalize on past investment and progress
and to develop needed new tools. ACET recommends the following steps to achieve
this goal:
• A concerted and sustained national effort to develop an effective new TB vaccine
should be made. A new vaccine is an urgent public health priority, and long-term
sources of private- and public-sector funds to support vaccine research should be
identified (4 ). NIH, CDC, and FDA should work closely with other partners, espe-
cially those in the private sector, to implement the strategies outlined in the
Blueprint for Tuberculosis Vaccine Development (5 ).
• Continued support should be provided for the development of specific skin-test
antigens and other methods to improve the diagnosis of latent TB infection.
• Studies to determine the immunologic and genetic markers related to disease
protection and progression from latent infection to active disease should be
expanded.
• Molecular, biochemical, and immunologic methods for rapid, accurate, and cost-
effective diagnosis of active TB and drug-resistant TB, including technologies
that would be useful in low-income countries, should be further developed and
refined.
• CDC should continue to support the TBTC, which, in turn, should seek expanded
collaboration in clinical studies. Enhanced private-sector support and public- and
private-sector collaboration are required for the development of new, effective
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drugs and other therapeutic interventions to improve the treatment of both
active and latent TB.
• Appropriate communication and behavior-change theories and models should
be used to develop effective messages, materials, and programs for health-care
providers on new developments in TB prevention and control. Successful imple-
mentation of new technologies requires education and training to effect changes
in health-care practice.
Recommit to the Global Battle Against TB
The interdependence of global TB and TB in the United States necessitates that the
United States make a firm commitment to the global battle against TB. The United
States has an important role in fostering international collaborations to address this
problem, and TB elimination efforts in this country could yield tools to improve the
effort worldwide. ACET recommends the following steps to achieve this goal:
• The United States should seek and promote a sustained commitment of the
nation’s scientific and political establishments to the global battle against TB.
• New diagnostic, treatment, and prevention tools developed as part of TB-
elimination efforts in the United States should be evaluated for potential applica-
tion in global settings. The United States also must commit to a concerted and
sustained national effort to develop an effective, new TB vaccine.
• CDC should expand and strengthen collaborations with international partners,
including USAID, WHO, the International Union Against Tuberculosis and Lung
Disease, the World Bank, and countries whose citizens contribute substantially to
the global TB burden and to TB morbidity in the United States.
Support Broad-Based Efforts for TB Prevention and Control at
National, State, and Local Levels
The efforts of public health providers alone were unable to prevent “dwindling
resources for TB prevention and control in the early 1970s [which] promoted the
decay of local TB control programs and set the stage for the disease’s subsequent
resurgence” (12 ). Leaders from other public health fields (e.g., HIV and sexually trans-
mitted disease [STD] prevention, cancer control, and violence prevention) have
encouraged the development of coalitions to achieve health promotion and disease
prevention objectives. In this context, a coalition consists of persons who represent
diverse organizations and constituencies and who agree to work together to achieve a
common goal (44 ). Coalitions offer several advantages, including diversity of exper-
tise and perspective, a capacity to mobilize public support, and a potential to improve
trust among groups that might otherwise be in competition. Similar mobilization of
new and nontraditional partners (e.g., managed care organizations) into TB coalitions
is needed to broaden the base of support for TB elimination. 
Strong advocacy for sustaining TB control and proceeding with TB elimination at
the local, state, and national levels is also necessary to ensure the commitment of
public support. To prevent another resurgence and to continue the present trend of
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decreasing TB morbidity, the support needed to effectively apply existing tools and
strategies for prevention and control must be maintained. As morbidity declines, find-
ing and treating cases of TB disease and latent infection could become less
cost-effective and will rely more on health-care providers outside TB-control
programs and health departments. Additional resources are needed for full imple-
mentation of effective elimination strategies, for biomedical research to develop the
tools required for TB elimination, and for efforts to control global TB. Achieving TB
elimination also will require the strategic use of mass media to promote TB elimina-
tion as an important public policy issue and advance it as a public policy initiative.
ACET recommends the following steps to achieve this goal:
• CDC should continue providing technical assistance to the American Thoracic
Society (ATS) and the American Lung Association (ALA) in their efforts to reinvig-
orate the National Coalition for the Elimination of Tuberculosis (NCET). NCET can
play a key role nationally in encouraging support for TB elimination and in pro-
viding leadership to state and local coalitions.
• Health departments, local ATS and ALA representatives, and other state and local
political partners should work with NCET to develop and strengthen local coali-
tions.
• CDC should work with state and local TB programs to develop partnerships with
business organizations, foundations, philanthropic groups, and with the busi-
ness, civic, and religious communities to mobilize support for TB elimination.
• CDC and state and local TB programs should work with health communications
experts to gain access to the media and to promote TB elimination as an impor-
tant public health concern for policymakers and opinion leaders, as well as for
communities and the general public.
CONCLUSION
Since ACET issued its strategic plan for TB elimination in the United States in 1989,
major changes have occurred in the epidemiology of TB and in the organization and
delivery of medical and public health services in the United States. A TB resurgence
was successfully curtailed, which demonstrated that investing in a strong public
health infrastructure at the national, state, and local levels could have an impact on TB
morbidity. The extent of the global TB epidemic and its increasing impact on TB mor-
bidity in the United States also were recognized. Although TB in the United States can
be contained by appropriate application of control methods, these events demon-
strate that TB elimination will require substantial technological advancements in
diagnosis, treatment, and prevention, including development of an effective vaccine.
The dynamic global nature of TB also demands that control efforts abroad be
enhanced to aid elimination in the United States. 
Thus, ACET reaffirms its commitment to TB elimination in the United States. Many
of the components needed to move from control to elimination are in place — a
proven public health infrastructure, effective standards of clinical and public health
practice, a coherent blueprint for TB education, and a framework for TB and vaccine
research. ACET calls for the establishment of new partnerships and coalitions to
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develop and support the resources and national consensus necessary to achieve TB
elimination. An effective and sustained TB-elimination campaign in the United States
could energize burgeoning international efforts to control TB worldwide and allow the
United States to assume a leadership role in this global struggle. 
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